UK markets closed

NIKKEI 225
37,552.16
+113.55(+0.30%)
HANG SENG
16,828.93
+317.24(+1.92%)
CRUDE OIL
83.33
+1.43(+1.75%)
GOLD FUTURES
2,342.10
-4.30(-0.18%)
DOW
38,509.63
+269.65(+0.71%)
Bitcoin GBP
53,617.36
+103.71(+0.19%)

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Roche Holding AG (RHHBF)

Other OTC - Other OTC Delayed price. Currency in USD

Add to watchlist

267.83

+11.52

(+4.50%)

As of 12:35PM EDT. Market open.

Trade prices are not sourced from all markets

All

Zacks
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
Zacks
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
Globe Newswire
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF